Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study
Recommended Phase 2 dose of venetoclax was 800 mg/day AED (Days 1-10 of 21-day cycles). Venetoclax combined with Cy-Topo chemotherapy had a predictable safety profile and showed modest clinical activity in these cohorts.
Authors
- Christian Flotho (ORCID: https://orcid.org/0000-0001-9367-0553)
- Daniel A. Morgenstern (ORCID: https://orcid.org/0000-0002-4859-1108)
- Andrew E. Place (ORCID: https://orcid.org/0000-0002-9604-4213)
- N. Corradini
- Sara Michele Federico (ORCID: https://orcid.org/0000-0002-5807-4876)
- Adam Luo (ORCID: https://orcid.org/0000-0002-3421-6913)
- Jeremy A. Ross (ORCID: https://orcid.org/0000-0002-8458-7819)
- Margaret E. Macy (ORCID: https://orcid.org/0000-0001-6446-9180)
- N J Gerber
- Maika Onishi
- Mark A. Rocco
- Giuseppe Barone (ORCID: https://orcid.org/0000-0003-3264-1913)
- Kelly C. Goldsmith (ORCID: https://orcid.org/0000-0001-8672-2298)
- Xin Chen (ORCID: https://orcid.org/0000-0002-5579-0447)
- Kieuhoa T. Vo
- Frank Scherer
- Mohamed Badawi
- Seong Lin Khaw
- Gauri Sunkersett
Institutions
- St. Jude Children's Research Hospital (US)
- Royal Children's Hospital (AU)
- University of Toronto (CA)
- Great Ormond Street Hospital for Children NHS Foundation Trust (GB)
- University Medical Center Freiburg (DE)
- Hospital for Sick Children (CA)
- AbbVie (United States) (US)
- Children's Hospital Colorado (US)
- Centre Léon Bérard (FR)
- AbbVie (Germany) (DE)
- University Children's Hospital Zurich (CH)
- UCSF Benioff Children's Hospital (US)
- Children's Healthcare of Atlanta (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1002/1545-5017.70178
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00